Evidence map›Paper›PMID 40719959›Full record

ReviewWorld journal of microbiology & biotechnology2025

Microbiota-driven epigenetic modifications in gastrointestinal cancer: Implications for pathogenesis and therapeutic strategies.

Haniye Rahimi-Kolour, Hedyeh Sadat Eshaghi, Elahe Shams, Fatemeh Sanjabi, Stefania Nobili, Hamideh Raeisi, Amir Sadeghi, Ehsan Nazemalhosseini-Mojarad, Nayeralsadat Fatemi

Abstract readReview
PubMed Publisher
In one paragraph

Review in World journal of microbiology & biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. The dual roles ofFrontiers in oncology · 2026
    Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Haniye Rahimi-KolourBasic and Molecular Epidemiology of Gastrointestinal Disorders Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Hedyeh Sadat EshaghiBasic and Molecular Epidemiology of Gastrointestinal Disorders Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Elahe ShamsBasic and Molecular Epidemiology of Gastrointestinal Disorders Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Fatemeh SanjabiDepartment of Medical Biotechnology, School F Allied Medicine, Iran University of Medical, Tehran, Iran.
Stefania NobiliDepartment of Neuroscience, Psychology, Drug Research and Child Health - NEUROFARBA - Pharmacology and Toxicology Section, University of Florence, Viale Pieraccini, 6, 50139, Florence, Italy.
Hamideh RaeisiGastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, P.O.Box: 16635-148, Tehran, Iran.
Amir SadeghiGastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, P.O.Box: 16635-148, Tehran, Iran.
Ehsan Nazemalhosseini-MojaradGastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, P.O.Box: 16635-148, Tehran, Iran. ehsanmojarad@gmail.com.
Nayeralsadat FatemiBasic and Molecular Epidemiology of Gastrointestinal Disorders Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran. n_fatemi_1363@yahoo.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The gastrointestinal (GI) tract hosts a complex microbiota that plays a crucial role in maintaining health and contributing to disease, including cancer. This narrative review explores the role of gut microbiota in driving epigenetic modifications associated with GI cancers. We highlight key bacterial phyla such as Firmicutes, Bacteroidetes, Actinobacteria, Proteobacteria, and Fusobacteria, and explain how their representative species, including Fusobacterium nucleatum, Bacteroides fragilis, Lactobacillus sp., and Escherichia coli, influence host gene expression through mechanisms such as DNA methylation, histone modification, and regulation of non-coding RNAs. Microbial metabolites, including short-chain fatty acids (SCFAs) like butyrate and secondary bile acids, affect the activity of epigenetic regulators such as DNA methyltransferases and histone deacetylases and have been implicated in the development of colorectal, gastric, liver, pancreatic, and esophageal cancers. By integrating recent scientific findings, this review underscores the potential of targeting microbiota-driven epigenetic pathways to improve prevention and treatment strategies for GI cancers.

Indexed as

BacteriaEpigenesis, GeneticGastrointestinal MicrobiomeGastrointestinal NeoplasmsAnimalsDNA MethylationGastrointestinal TractHumansEpigenetic changesGastrointestinal tractMicrobiota

Identifiers

PMID40719959

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.